Results of induction/consolidation... | American Society of Hematology

Results of induction/consolidation therapies with or without daratumumab

Variable	VTd 28 d	D-VTd 28 d	RVd 21 d	VRD 28 d	RVd 21 d	D-RVd 21 d	KRd 28 d
Variable	CASSIOPEIA trial⁴	CASSIOPEIA trial⁴	IFM 2009 trial⁵	GEM 2012 trial⁹	Voorhees et al	Voorhees et al	FORTE trial¹⁰
No. of cycles	4 induction	4 induction	3 induction	6 induction	4 induction	4 induction	4 induction
No. of cycles	2 consolidation	2 consolidation	2 consolidation	2 consolidation	2 consolidation	2 consolidation	4 consolidation
No. of patients	542	543	350	458	102	99	158
Postinduction, %
VGPR or better	56	65	47	67	57	72	67
CR or better	9	14		33	13	19	34
s-CR	6.5	7			7	12	8
Postconsolidation, %
VGPR or better	78	83	78	75.5	73	91	87
CR or better	26	39		50	42	51.5	62
s-CR	20	29			32	42	41

Variable	VTd 28 d	D-VTd 28 d	RVd 21 d	VRD 28 d	RVd 21 d	D-RVd 21 d	KRd 28 d
Variable	CASSIOPEIA trial⁴	CASSIOPEIA trial⁴	IFM 2009 trial⁵	GEM 2012 trial⁹	Voorhees et al	Voorhees et al	FORTE trial¹⁰
No. of cycles	4 induction	4 induction	3 induction	6 induction	4 induction	4 induction	4 induction
No. of cycles	2 consolidation	2 consolidation	2 consolidation	2 consolidation	2 consolidation	2 consolidation	4 consolidation
No. of patients	542	543	350	458	102	99	158
Postinduction, %
VGPR or better	56	65	47	67	57	72	67
CR or better	9	14		33	13	19	34
s-CR	6.5	7			7	12	8
Postconsolidation, %
VGPR or better	78	83	78	75.5	73	91	87
CR or better	26	39		50	42	51.5	62
s-CR	20	29			32	42	41

D-RVd, daratumumab-RVd; D-VTd, daratumumab, bortezomib, thalidomide, and dexamethasone; KRd, carfilzomib, lenalidomide, and dexamethasone; s-CR, stringent CR; VGPR, very good partial response; VRD, bortezomib, lenalidomide, and dexamethasone; VTd, bortezomib, thalidomide, and dexamethasone.

View Large

This Feature Is Available To Subscribers Only